ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Impact · against what's priced in

Alnylam Pharmaceuticals faces significant downward pressure due to lowered 2026 TTR sales guidance and a subsequent securities fraud investigation. While Carrier Global is also mentioned as subject to an investigation, the impact is likely lower given the nature of the legal announcement.

ALNY−0.80

No priced-in read yet